The Bethesda Handbook of Clinical Hematology by Rodgers Griffin P. & Young Neal S

The Bethesda Handbook of Clinical Hematology by Rodgers Griffin P. & Young Neal S

Author:Rodgers, Griffin P. & Young, Neal S. [Rodgers, Griffin P. & Young, Neal S.]
Language: eng
Format: epub
Publisher: Lippincott Williams & Wilkins
Published: 2013-05-05T14:00:00+00:00


References

1. Blume KG, Thomas ED. A review of autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2000;6:1-12.

2. Thomas ED. Bone marrow transplantation: a review. Semin Hematol. 1999;36:95-103.

3. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med. 1996;335:91-97.

4. Krishnan A, Pasquini MC, Logan B, et al. Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncol. 2011;12:1195-1203.

5. Cavo M, Rajkumar SV, Palumbo A, et al. International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood. 2011;117: 6063-6073.

6. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med. 1995;333: 1540-1545.

7. Antman KH. Randomized trials of high dose chemotherapy for breast cancer. Biochim Biophys Acta. 2001;1471: M89-98.

8. Pico JL, Rosti G, Kramar A, et al. A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. Ann Oncol. 2005;16:1152-1159.

9. Voss MH, Feldman DR, Motzer RJ. High-dose chemotherapy and stem cell transplantation for advanced testicular cancer. Expert Rev Anticancer Ther. 2011;11:1091-1103.

10. Childs RW. Allogeneic hematopoietic cell transplantation. In: De Vita VJ, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. London: Lippincott Williams and Wilkins; 2011;2244-2261.

11. Mathe G, Amiel JL, Schwarzenberg L, et al. Adoptive immunotherapy of acute leukemia: experimental and clinical results. Cancer Res. 1965;25:1525-1531.

12. Storb R. Allogeneic hematopoietic stem cell transplantation—yesterday, today, and tomorrow. Exp Hematol. 2003;31:1-10.

13. Boelens JJ, Prasad VK, Tolar J, et al. Current international perspectives on hematopoietic stem cell transplantation for inherited metabolic disorders. Pediatr Clin North Am. 2010;57:123-145.

14. Smith AR, Gross TG, Baker KS. Transplant outcomes for primary immunodeficiency disease. Semin Hematol. 2010;47:79-85.

15. Antin JH. Stem cell transplantation-harnessing of graft-versus-malignancy. Curr Opin Hematol. 2003;10:440-444.

16. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75:555-562.

17. Riddell SR, Berger C, Murata M, et al. The graft versus leukemia response after allogeneic hematopoietic stem cell transplantation. Blood Rev. 2003;17:153-162.

18. Brunstein CG, Fuchs EJ, Carter SL, et al. Alternative donor transplantation after intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood. 2011;118:282-288.

19. Bensinger WI, Martin PJ, Storer B, et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med. 2001;344:175-181.

20. Claudio Anasetti BRL, Lee SJ, Waller EK, et al. Increased incidence of chronic graft-versus-host disease (GVHD) and no survival advantage with filgrastim-mobilized peripheral blood stem cells (PBSC) compared to bone marrow (bm) transplants from unrelated donors: results of blood and marrow transplant clinical trials network (BMT CTN) protocol 0201, a phase III, prospective, randomized trial. Blood. (ASH Annual Meeting Abstracts) 2011;118:1.

21. Schlenk RF, Dohner K, Krauter J, et al.



Download



Copyright Disclaimer:
This site does not store any files on its server. We only index and link to content provided by other sites. Please contact the content providers to delete copyright contents if any and email us, we'll remove relevant links or contents immediately.